Enabling cell culture technologies for the intensification & scale-up of viral vector manufacturing

Cell & Gene Therapy Insights 2023; 9(11), 1441–1445

DOI: 10.18609/cgti.2023.187

Published: 29 November 2023
Julien Robitaille

National Research Council Canada,
Human Health Therapeutics Research Center

 “For as long as the pressure to reduce the cost of goods for gene therapy manufacturing persists, novel cell culture platforms and continuous improvement in the production of AAV and other relevant viral vectors will be needed.”